Purchase this article with an account.
F. Boscia, N. Cardascia, C. Furino, C. Sborgia; Photodynamic Therapy With Verteporfin for Chronic Central Serous Chorioretinopathy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4066.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the efficacy of photodynamic therapy (PDT) with verteporfin for chronic central serous chorioretinopathy (CCSC). Methods: Eleven eyes of 11 patients (age: 58±2.9 years, 8 males, 3 female) with CCSC and pigment epithelium detachment (PED) revealed by fluorescein angiography (FA), indocyanine–green angiography (ICG–A) and optical coherence tomography (OCT) underwent PDT with verteporfin following TAP protocol. The treatment covered the PED and focal areas of hyperpermeability. Functional and anatomical outcomes were observed at 1, 3, 6 and 12 months after the treatment by best corrected visual acuity (BCVA) assessment using ETDRS chart, FA, ICG–A and OCT. Results: After 12 months, mean visual acuity remained stable, varying from 0.22 ±0.09 to 0.22±0.18 LogMAR (p=0.97). At the end of the follow up, BCVA remained stable in 4 eyes, improved in 6 and decreased in 1 eye. PED and focal areas of hyperpermeability disappeared after 1 month in 10 eyes, and remained invaried at the end of the follow up. One eye developed a choroidal neovascularization (CNV) which was successfully treated with 2 courses of PDT. Conclusions: Photodynamic therapy with verteporfin appears to have a beneficial effect in patients with CCSC by reducing fluid leakage, subretinal fluid accumulation, and serous detachment with resultant improvement in vision. Still some reservation exist as the possible stimulation of CNV.
This PDF is available to Subscribers Only